OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00940303
First received: July 6, 2009
Last updated: October 6, 2014
Last verified: October 2014
  Purpose

This single arm study will assess progression-free survival, feasibility of use and safety of Avastin in combination with 5-FU/FA, oxaliplatin and irinotecan (F OLFOXIRI) as first line treatment in patients with metastatic colorectal cancer.

Patients will receive up to 12 bi-weekly cycles of Avastin (5mg/kg iv) in combi nation with this standard neoadjuvant chemotherapy regimen followed by up to 40 bi-weekly cycles with Avastin plus 5-FU/FA. The anticipated time on study treatm ent is until disease progression, and the target sample size is <100 individuals


Condition Intervention Phase
Colorectal Cancer
Drug: 5-FU
Drug: bevacizumab [Avastin]
Drug: irinotecan
Drug: leucovorin
Drug: oxaliplatin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: assessed every 8 weeks up to week 102, 3-monthly during follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival; proportion of patients achieving R0 resectability; objective response rate (complete response [CR] and partial response [PR]); proportion of patients completing 12 cycles of chemotherapy. [ Time Frame: assessed every 4 weeks up to week 102 and at the end of follow-up period ] [ Designated as safety issue: No ]
  • Proportion of patients with NCI-CTC grade 3-5 adverse events; adverse events, laboratory parameters, ECOG performance status. [ Time Frame: Throughout study, laboratory analyses every 2 weeks, ECOG assessment every 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 97
Study Start Date: June 2009
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: 5-FU
3200mg/m2 continuous iv infusions, day 1 every 2 weeks
Drug: bevacizumab [Avastin]
5mg/kg iv infusion, day 1 every 2 weeks
Drug: irinotecan
165mg/m2 iv infusion, day 1 every 2 weeks
Drug: leucovorin
200mg/m2 iv infusion, day 1 every 2 weeks
Drug: oxaliplatin
85mg/m2 iv infusion, day 1 every 2 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, 18-70 years of age;
  • metastatic colorectal cancer scheduled for standard first line chemotherapy;
  • at least 1 measurable lesion;
  • ECOG performance score of 0 or 1.

Exclusion Criteria:

  • prior chemotherapy for metastatic colorectal cancer;
  • prior (neo)adjuvant chemotherapy/radiotherapy of a non-metastatic malignancy completed within 6 months prior to study entry;
  • concomitant malignancies other CRC;
  • history or evidence of CNS disease unrelated to cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00940303

Locations
Germany
Berlin, Germany, 13347
Berlin, Germany, 13353
Bochum, Germany, 44791
Celle, Germany, 29221
Celle, Germany, 29223
Dessau-Roßlau, Germany, 06847
Freiburg, Germany, 79106
Fulda, Germany, 36043
Hamburg, Germany, 22087
Hamburg, Germany, 20246
Hannover, Germany, 30171
Leer, Germany, 26789
Magdeburg, Germany, 39130
Magdeburg, Germany, 39120
Nürnberg, Germany, 90419
Stade, Germany, 21680
Villingen-Schwenningen, Germany, 78052
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00940303     History of Changes
Other Study ID Numbers: ML20514, 2008-001180-11
Study First Received: July 6, 2009
Last Updated: October 6, 2014
Health Authority: Germany: Paul-Ehrlich-Institut

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014